2026 Q2 - tulosraportti
50 päivää sitten
‧48 min
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 325 | - | - | ||
| 3 257 | - | - | ||
| 16 743 | - | - | ||
| 1 760 | - | - | ||
| 17 973 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
·12 t sittenLegal tracks and evidence in a lawsuit: To convince the court that the cancer program VB10.NEO was a depreciable asset (which grants entitlement to a gains and losses account) and not goods developed for sale, Nykodes lawyers will likely focus on three main arguments: 1. Procedural error (The right to be heard): Since the Tax Appeal Board introduced the reclassification as a completely new argument during the board proceedings themselves, Nykode never got the opportunity to counter this before the decision was made. This violates the fundamental administrative law principle of prior warning and contradiction, which alone can make the decision invalid. 2. Commercial substance in license agreements: Nykode will use industry experts to document that a license and collaboration agreement is not the same as a sale. In a sale, you permanently give up control in exchange for a settlement. In a licensing arrangement, Nykode retains ownership of the platform technology and continues working as an active development partner. The financial goal is long-term, ongoing royalty revenues over decades – which defines a depreciable asset. 3. The purpose at the time of development: Tax law emphasizes what the predominant purpose was when the asset was acquired or developed. Nykode will present internal board minutes, research plans and strategy documents proving that VB10.NEO was developed as a core component in the companys own research portfolio, and that a partnership agreement was only one of several possible operational models to finance further development. I really cannot see anything other than that they will win in a lawsuit, unless the tax authorities reverse course before it reaches the court and listen to their OWN board's recommendation.
·15 t sittenFrom MedWatch: Biontech missed one of two main goals in cancer study. Nykode Therapeutics director Michael Engsig believes a further setback for the competitor can make the path easier for the biotech company. Anyone who has access to the full article? https://medwatch.no/nyheter/legemidler_biotek/article19735396.ece
Biontechs investigational mRNA-based cancer treatment failed to reach the first of two primary endpoints in a phase 2/3 trial in patients with HPV16-positive head and neck cancer. The combination of BNT113 and Keytruda did not show a statistically significant improvement in progression-free survival (the time patients lived without their disease worsening (PFS)), compared to Keytruda alone, Biontech stated on Tuesday. The trial has two co-primary endpoints: progression-free survival and overall survival. It is now continuing to investigate whether the treatment prolongs patients' lives, following a recommendation from an independent committee, Biontech states. Overall survival is considered the gold standard in cancer trials because it shows whether the treatment actually prolongs life. Biontech states that the trial can still be considered successful if the treatment shows a statistically significant improvement in overall survival, even if the first primary endpoint was not reached. Nykode sees opportunities The Norwegian biotech company Nykode Therapeutics is also developing a therapeutic cancer vaccine against HPV16-positive head and neck cancer. The company is testing the drug candidate abi-suva in combination with Keytruda in the phase 2 trial Abili-T. When asked by Nykode CEO Michael Engsig about what Biontech's results mean for the company's assessment of the opportunities to succeed with the cancer vaccine abi-suva, and whether the results could lead to changes in strategy, the answer is: – The short answer is that it does not change our strategy in the short term, and in the long term our path becomes simpler. He points out that Biontech is still investigating whether the treatment has an effect on overall survival, and that the outcome could have significance for the competitive situation. – If Biontech also fails to reach its efficacy endpoint for survival, it primarily means that the last competitor ahead of abi-suva falls away, and that abi-suva can thus become both best and first-in-class, he tells MedWatch. Engsig believes Nykode's candidate has shown promising results compared to other cancer vaccines. – We have fundamentally been quite optimistic regarding abi-suva's advantages compared to the other comparable cancer vaccines, he says. – Where Biontech previously has only shown data from 15 patients, abi-suva has shown very promising tendencies in three different patient types with a total of around 100 patients. But when you are first-in-class, the development pathway naturally becomes a bit simpler. – Will continue the strategy Nykode started treatment of the first patient in the Abili-T trial in May, which investigates abi-suva in combination with Keytruda as first-line treatment in recurrent or metastatic HPV16-positive head and neck cancer. Engsig emphasizes that the company will continue the development work as planned. – In other words, Nykode's strategy is unchanged. The first priority is to get abi-suva tested in first-line treatment of head and neck cancer (the Abili-T trial), as well as investigate the possibility of expanding to earlier stages, where we believe the opportunities are at least as great for cancer vaccines. He also believes that the results from Biontech can give Nykode an opportunity to show the difference between the companies' vaccine technologies. – In addition, this is a good opportunity to demonstrate Nykodes technology up against the RNA vaccine technology from Biontech. If we succeed with abi-suva where Biontech failed, it will likely also have breakthrough impact for VB10.NEO. VB10.NEO is Nykode's individually tailored cancer vaccine candidate, which is being developed on the company's proprietary technology platform
·19 t sittenWhy is Nykode falling over 10 % in a week without news???
When Mr. Market offers his shares at a giveaway price, you just have to accept.
19 t sittenCertainly tempting to buy at these levels.
Would have been fun with some tailwind in this - see Michael E. proud at the quarterly presentation and that the company succeeds
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
50 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·12 t sittenLegal tracks and evidence in a lawsuit: To convince the court that the cancer program VB10.NEO was a depreciable asset (which grants entitlement to a gains and losses account) and not goods developed for sale, Nykodes lawyers will likely focus on three main arguments: 1. Procedural error (The right to be heard): Since the Tax Appeal Board introduced the reclassification as a completely new argument during the board proceedings themselves, Nykode never got the opportunity to counter this before the decision was made. This violates the fundamental administrative law principle of prior warning and contradiction, which alone can make the decision invalid. 2. Commercial substance in license agreements: Nykode will use industry experts to document that a license and collaboration agreement is not the same as a sale. In a sale, you permanently give up control in exchange for a settlement. In a licensing arrangement, Nykode retains ownership of the platform technology and continues working as an active development partner. The financial goal is long-term, ongoing royalty revenues over decades – which defines a depreciable asset. 3. The purpose at the time of development: Tax law emphasizes what the predominant purpose was when the asset was acquired or developed. Nykode will present internal board minutes, research plans and strategy documents proving that VB10.NEO was developed as a core component in the companys own research portfolio, and that a partnership agreement was only one of several possible operational models to finance further development. I really cannot see anything other than that they will win in a lawsuit, unless the tax authorities reverse course before it reaches the court and listen to their OWN board's recommendation.
- ·15 t sittenFrom MedWatch: Biontech missed one of two main goals in cancer study. Nykode Therapeutics director Michael Engsig believes a further setback for the competitor can make the path easier for the biotech company. Anyone who has access to the full article? https://medwatch.no/nyheter/legemidler_biotek/article19735396.eceBiontechs investigational mRNA-based cancer treatment failed to reach the first of two primary endpoints in a phase 2/3 trial in patients with HPV16-positive head and neck cancer. The combination of BNT113 and Keytruda did not show a statistically significant improvement in progression-free survival (the time patients lived without their disease worsening (PFS)), compared to Keytruda alone, Biontech stated on Tuesday. The trial has two co-primary endpoints: progression-free survival and overall survival. It is now continuing to investigate whether the treatment prolongs patients' lives, following a recommendation from an independent committee, Biontech states. Overall survival is considered the gold standard in cancer trials because it shows whether the treatment actually prolongs life. Biontech states that the trial can still be considered successful if the treatment shows a statistically significant improvement in overall survival, even if the first primary endpoint was not reached. Nykode sees opportunities The Norwegian biotech company Nykode Therapeutics is also developing a therapeutic cancer vaccine against HPV16-positive head and neck cancer. The company is testing the drug candidate abi-suva in combination with Keytruda in the phase 2 trial Abili-T. When asked by Nykode CEO Michael Engsig about what Biontech's results mean for the company's assessment of the opportunities to succeed with the cancer vaccine abi-suva, and whether the results could lead to changes in strategy, the answer is: – The short answer is that it does not change our strategy in the short term, and in the long term our path becomes simpler. He points out that Biontech is still investigating whether the treatment has an effect on overall survival, and that the outcome could have significance for the competitive situation. – If Biontech also fails to reach its efficacy endpoint for survival, it primarily means that the last competitor ahead of abi-suva falls away, and that abi-suva can thus become both best and first-in-class, he tells MedWatch. Engsig believes Nykode's candidate has shown promising results compared to other cancer vaccines. – We have fundamentally been quite optimistic regarding abi-suva's advantages compared to the other comparable cancer vaccines, he says. – Where Biontech previously has only shown data from 15 patients, abi-suva has shown very promising tendencies in three different patient types with a total of around 100 patients. But when you are first-in-class, the development pathway naturally becomes a bit simpler. – Will continue the strategy Nykode started treatment of the first patient in the Abili-T trial in May, which investigates abi-suva in combination with Keytruda as first-line treatment in recurrent or metastatic HPV16-positive head and neck cancer. Engsig emphasizes that the company will continue the development work as planned. – In other words, Nykode's strategy is unchanged. The first priority is to get abi-suva tested in first-line treatment of head and neck cancer (the Abili-T trial), as well as investigate the possibility of expanding to earlier stages, where we believe the opportunities are at least as great for cancer vaccines. He also believes that the results from Biontech can give Nykode an opportunity to show the difference between the companies' vaccine technologies. – In addition, this is a good opportunity to demonstrate Nykodes technology up against the RNA vaccine technology from Biontech. If we succeed with abi-suva where Biontech failed, it will likely also have breakthrough impact for VB10.NEO. VB10.NEO is Nykode's individually tailored cancer vaccine candidate, which is being developed on the company's proprietary technology platform
- ·19 t sittenWhy is Nykode falling over 10 % in a week without news???When Mr. Market offers his shares at a giveaway price, you just have to accept.
- 19 t sittenCertainly tempting to buy at these levels.Would have been fun with some tailwind in this - see Michael E. proud at the quarterly presentation and that the company succeeds
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 325 | - | - | ||
| 3 257 | - | - | ||
| 16 743 | - | - | ||
| 1 760 | - | - | ||
| 17 973 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Välittäjätilasto
Dataa ei löytynyt
2026 Q2 - tulosraportti
50 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 - tulosraportti 25.11. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 - tulosraportti 26.8. | ||
2026 Q1 - tulosraportti 27.5. | ||
2025 Q4 - tulosraportti 25.2. | ||
2025 Q3 - tulosraportti 24.11.2025 | ||
2025 Q2 - tulosraportti 27.8.2025 |
Tuotteita joiden kohde-etuutena tämä arvopaperi
Foorumi
Liity keskusteluun Nordnet Socialissa
- ·12 t sittenLegal tracks and evidence in a lawsuit: To convince the court that the cancer program VB10.NEO was a depreciable asset (which grants entitlement to a gains and losses account) and not goods developed for sale, Nykodes lawyers will likely focus on three main arguments: 1. Procedural error (The right to be heard): Since the Tax Appeal Board introduced the reclassification as a completely new argument during the board proceedings themselves, Nykode never got the opportunity to counter this before the decision was made. This violates the fundamental administrative law principle of prior warning and contradiction, which alone can make the decision invalid. 2. Commercial substance in license agreements: Nykode will use industry experts to document that a license and collaboration agreement is not the same as a sale. In a sale, you permanently give up control in exchange for a settlement. In a licensing arrangement, Nykode retains ownership of the platform technology and continues working as an active development partner. The financial goal is long-term, ongoing royalty revenues over decades – which defines a depreciable asset. 3. The purpose at the time of development: Tax law emphasizes what the predominant purpose was when the asset was acquired or developed. Nykode will present internal board minutes, research plans and strategy documents proving that VB10.NEO was developed as a core component in the companys own research portfolio, and that a partnership agreement was only one of several possible operational models to finance further development. I really cannot see anything other than that they will win in a lawsuit, unless the tax authorities reverse course before it reaches the court and listen to their OWN board's recommendation.
- ·15 t sittenFrom MedWatch: Biontech missed one of two main goals in cancer study. Nykode Therapeutics director Michael Engsig believes a further setback for the competitor can make the path easier for the biotech company. Anyone who has access to the full article? https://medwatch.no/nyheter/legemidler_biotek/article19735396.eceBiontechs investigational mRNA-based cancer treatment failed to reach the first of two primary endpoints in a phase 2/3 trial in patients with HPV16-positive head and neck cancer. The combination of BNT113 and Keytruda did not show a statistically significant improvement in progression-free survival (the time patients lived without their disease worsening (PFS)), compared to Keytruda alone, Biontech stated on Tuesday. The trial has two co-primary endpoints: progression-free survival and overall survival. It is now continuing to investigate whether the treatment prolongs patients' lives, following a recommendation from an independent committee, Biontech states. Overall survival is considered the gold standard in cancer trials because it shows whether the treatment actually prolongs life. Biontech states that the trial can still be considered successful if the treatment shows a statistically significant improvement in overall survival, even if the first primary endpoint was not reached. Nykode sees opportunities The Norwegian biotech company Nykode Therapeutics is also developing a therapeutic cancer vaccine against HPV16-positive head and neck cancer. The company is testing the drug candidate abi-suva in combination with Keytruda in the phase 2 trial Abili-T. When asked by Nykode CEO Michael Engsig about what Biontech's results mean for the company's assessment of the opportunities to succeed with the cancer vaccine abi-suva, and whether the results could lead to changes in strategy, the answer is: – The short answer is that it does not change our strategy in the short term, and in the long term our path becomes simpler. He points out that Biontech is still investigating whether the treatment has an effect on overall survival, and that the outcome could have significance for the competitive situation. – If Biontech also fails to reach its efficacy endpoint for survival, it primarily means that the last competitor ahead of abi-suva falls away, and that abi-suva can thus become both best and first-in-class, he tells MedWatch. Engsig believes Nykode's candidate has shown promising results compared to other cancer vaccines. – We have fundamentally been quite optimistic regarding abi-suva's advantages compared to the other comparable cancer vaccines, he says. – Where Biontech previously has only shown data from 15 patients, abi-suva has shown very promising tendencies in three different patient types with a total of around 100 patients. But when you are first-in-class, the development pathway naturally becomes a bit simpler. – Will continue the strategy Nykode started treatment of the first patient in the Abili-T trial in May, which investigates abi-suva in combination with Keytruda as first-line treatment in recurrent or metastatic HPV16-positive head and neck cancer. Engsig emphasizes that the company will continue the development work as planned. – In other words, Nykode's strategy is unchanged. The first priority is to get abi-suva tested in first-line treatment of head and neck cancer (the Abili-T trial), as well as investigate the possibility of expanding to earlier stages, where we believe the opportunities are at least as great for cancer vaccines. He also believes that the results from Biontech can give Nykode an opportunity to show the difference between the companies' vaccine technologies. – In addition, this is a good opportunity to demonstrate Nykodes technology up against the RNA vaccine technology from Biontech. If we succeed with abi-suva where Biontech failed, it will likely also have breakthrough impact for VB10.NEO. VB10.NEO is Nykode's individually tailored cancer vaccine candidate, which is being developed on the company's proprietary technology platform
- ·19 t sittenWhy is Nykode falling over 10 % in a week without news???When Mr. Market offers his shares at a giveaway price, you just have to accept.
- 19 t sittenCertainly tempting to buy at these levels.Would have been fun with some tailwind in this - see Michael E. proud at the quarterly presentation and that the company succeeds
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 2 325 | - | - | ||
| 3 257 | - | - | ||
| 16 743 | - | - | ||
| 1 760 | - | - | ||
| 17 973 | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Rahastot ja ETF:t, joilla on osaketta
Mikään rahasto ei ilmoita osaketta kymmenen suurimman omistuksensa joukossa.
Asiakkaat katsoivat myös
Välittäjätilasto
Dataa ei löytynyt